Phase 1 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older, of any gender
- People who have been diagnosed with eosinophilic leukemia according to the World Health Organization's 2022 diagnostic guidelines
- People whose leukemia cells show a specific protein marker (called IL-5Rα or CD125) on at least 50% of the abnormal blood cells
- People whose eosinophilic leukemia has not responded well to standard treatments (such as imatinib, steroids, interferon-alpha, or chemotherapy), or whose disease came back or got worse within 6 months of achieving remission
- People whose liver blood test results are within an acceptable range (confirm with trial site for specific values)
- People whose heart is pumping well enough, as measured by an ultrasound of the heart showing a pumping function above 50%
- People whose blood oxygen level is at least 92% while breathing normal room air, without extra oxygen support
- People with a life expectancy of more than 3 months
- People who are generally well enough to carry out daily activities with little or no limitation (as assessed using a standard medical scale called ECOG, with a score of 0 or 1)
- People of childbearing potential who agree to use effective contraception before, during, and for 6 months after receiving the trial treatment
- People who are willing to take part and are able to understand and sign a consent form voluntarily
Who may not be able to join:
- People with a history of epilepsy or other conditions affecting the brain or nervous system
- People who test positive for Hepatitis B surface antigen, certain Hepatitis B markers with detectable virus in the blood, Hepatitis C antibodies, HIV antibodies, or syphilis
- People with a history of abnormal heart rhythm (specifically prolonged QT interval) or serious heart disease
- People who have an active infection that is not currently under control
- People with any other condition that the trial doctor believes could increase risk or affect the trial results (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: He Huang, MD, First Affiliated Hospital of Zhejiang University
Phone: 0571-88208002
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dose-limiting toxicity (DLT); Incidence of treatment-emergent adverse events (TEAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.